Skip to main content
. 2019 Jul 9;18(3):2724–2732. doi: 10.3892/ol.2019.10596

Figure 2.

Figure 2.

MLN4924 + cisplatin treatment suppresses pancreatic cancer proliferation in vitro. (A) MLN4924 inhibited the neddylation of CUL1 in pancreatic cancer cells. Cells were treated with MLN4924 for 24 h and analyzed by western blotting. (B) Effects of MLN4924 + cisplatin treatment on the viability of BXPC3 and SW1990 cells in vitro. Cells were treated with DMSO, MLN4924, cisplatin or MLN4924 + cisplatin for 48 h (0.3 µM MLN; 0.5 µM cisplatin) and viability was assessed using ATPlite and Cell Counting Kit-8 assays, respectively. (C and D) Effects of MLN4924 + cisplatin treatment on clonogenic survival. BXPC3 and SW1990 cells were treated with DMSO, MLN4924, cisplatin or MLN4924 + cisplatin for 12 days (0.3 µM MLN; 0.5 µM cisplatin). All experiments were repeated 3 times and the results are presented as the mean ± standard deviation. ***P<0.001. DMSO, dimethyl sulfoxide; CON, control; MLN, MLN4924; CIS, cisplatin; NEDD8, Neural precursor cell-expressed, developmentally downregulated 8; CULl, cullin 1.